69 results
424B3
OCUP
Ocuphire Pharma Inc
16 Feb 24
Prospectus supplement
4:31pm
, social, and governance matters and any related reporting obligations may impact our business;
if we fail to comply with the continued listing standards
8-K
p3ank6 4r2xhkco9ux
1 Nov 23
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
4:21pm
424B5
ffrq1diz
14 Aug 23
Prospectus supplement for primary offering
8:00am
8-K
EX-10.1
zn3i4vk7mirxw5vk7fk
7 Nov 22
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
4:16pm
8-K
oz4d 3i3o
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
8-K
EX-14.1
26p0adm
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
8-K
EX-10.9
p9alyi8b
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
424B3
b4jqxz oqhajzbozbb8
2 Oct 20
Prospectus supplement
9:25am